UnknownNot Applicable

Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer

China50 participantsStarted 2021-01-01

Plain-language summary

The early symptoms of pancreatic cancer are not obvious, and the early diagnosis rate is low. For most patients with pancreatic cancer,palliative chemotherapy is the only choice .At present, The guidance of NCCN guidelines on the selection of chemotherapy regimens for patients with advanced pancreatic cancer is only based on the physical condition(the ECOG score), which is one of the important reasons for the poor efficacy of chemotherapy in patients with advanced pancreatic cancer.Therefore, it is urgent to group pancreatic cancer patients according to tumor molecular typing and heterogeneity of response to chemotherapy drugs accurately,so as to guide the personalized treatment of patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years old, male or female;
✓. Locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed by histopathology / cytology of the primary and / or metastatic lesions and not suitable for surgical resection, and don't receive chemotherapy;
✓. According to the evaluation criteria of solid tumor efficacy(RECIST 1.1), there should be at least one measurable lesion (non nodular lesion with the longest diameter of 210 mm, or nodular lesion with the shortest diameter of more than 15 mm);
✓. Patients voluntarily participate in this study, sign informed consent, have good compliance, and cooperate with follow-up.

Exclusion criteria

✕. Pancreatic ductal adenocarcinoma is diagnosed without histopathology / cytology;
✕. The target lesion has received local non-drug therapy (including radiotherapy, physical and / or chemical ablation, etc.), and there is no imaging progression;
✕. If the central nervous system metastasis is known, MRI should be performed to exclude it.

What they're measuring

Accuracy of using the model to predict the therapeutic effect of drugs

Timeframe: 1.5 years

Trial details

NCT IDNCT05168254

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-01

Contact for this trial

Yao Zhang

18019076695 zyrjxh97@sjtu.edu.cn

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma, PDAC trials